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Background: G9a/GLP lysine methyltransferases 
mono- and di-methylate histone H3 lysine 9 
(H3K9me2). 
Results: Widely Interspaced Zinc Finger (WIZ) 
regulates H3K9me2 levels through a mechanism 
that involves retention of G9a on chromatin. 
Conclusion: G9a/GLP/WIZ complex has unique 
functions when bound to chromatin that are 
independent of the H3K9me2 mark. 
Significance: Combining pharmacologic and 
genetic manipulations is essential to any 
translational hypotheses related to G9a function. 
 
Abstract 
 G9a and GLP lysine methyltransferases 
form a heterodimeric complex that is 
responsible for the majority of histone H3 
lysine 9 mono- and di-methylation 
(H3K9me1/me2).  Widely Interspaced Zinc 
finger (WIZ) associates with the G9a/GLP 
protein complex, but its role in mediating lysine 
methylation is poorly defined.  Here, we show 
that WIZ regulates global H3K9me2 levels by 
facilitating the interaction of G9a with 
chromatin.  Disrupting the association of 
G9a/GLP with chromatin by depleting WIZ 
results in altered gene expression and protein-
protein interactions that are distinguishable 
from that of small molecule-based inhibition of 
G9a/GLP in support of discrete functions of the 
G9a/GLP/WIZ/chromatin complex in addition 
to H3K9me2 methylation. 
 
Introduction 
 Posttranslational modification of amino 
terminal lysines of histone proteins is associated 
with diverse biological consequences including 
changes in transcription and chromatin 
architecture.  Lysine methylation is commonly 
performed by Su(var)3-9-Enhancer of zeste-
Trithorax (SET)-domain containing proteins (1-5).  
Two important members of this family are the G9a 
(EHMT2) and GLP (EHMT1) lysine 
methyltransferases (KMTs).  These enzymes are 
implicated in a variety of disease and biological 
processes (6), demonstrate both co-activator and 
co-repressor functions (6-8), and interact with 
other SET-domain-containing proteins including 
SETDB1, Suv39H1, and the PRC2 complex (9,10).  
G9a and GLP show similar substrate specificities 
(11-13); they can methylate histones H1 
(11,12,14), H3K27 (11,15), H3K56 (16) as well as 
a number of non-histone proteins (17-21), but are 
best characterized as the major KMTs involved in 
mono- and di-methylation of H3K9 (11,22-25).   
Transcriptional silencing and H3K9 
mono- and di-methylation functions of G9a and 
GLP are dependent on heterodimerization through 
their respective SET domains (25).  Studies in 
mouse G9a and Glp knockout cells demonstrate 
that loss of either G9a or GLP results in 
degradation of the remaining protein partner 
(13,25).  Reconstitution of these cells with a 
heteromeric complex consisting of either a G9a or 
a GLP catalytic mutant suggests that the catalytic 
activity of GLP, but not G9a, is dispensable for 
H3K9 methylation (13). 
While the interaction between G9a and 
GLP has been studied extensively, the interaction 
between these proteins and a third complex 
member, Widely Interspaced Zinc finger (WIZ) 
protein, is less well understood.   The mouse Wiz 
gene products were identified as two alternatively 
spliced isoforms, WizS and WizL, which were 
abundantly expressed in the brain compared to 
other tissue types (26).  WIZ has C2H2-type zinc 
finger motifs that were originally characterized in 
the Xenopus TFIIIA (27), and Drosophila Krüppel 
transcription factors (28).  Typical C2H2-type zinc 
finger motifs are separated by 7 amino acids.  The 
WIZ zinc fingers are widely spaced, being 
separated by distances ranging from 16 to 258 
amino acids in mouse (26), and from 16 to 263 
amino acids in the longest human splice variant.  
Mutational analysis demonstrated that WIZ 
interacts with the C-terminal SET domain of G9a 
or GLP through its C-terminal zinc finger (29).  
WIZ has been shown to bridge the interaction 
between G9a/GLP and the transcriptional co-
repressors C-terminal Binding Protein 1 (CtBP1), 
and CtBP2 possibly to help recruit G9a/GLP to 
specific genomic loci (29), and is a non-histone 
methylation target for G9a (18). 
WIZ has also been implicated in G9a and 
GLP protein stability (29).  We found that WIZ 
knockdown leads to H3K9me2 loss that is not 
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attributable to degradation of G9a or GLP protein; 
rather, that WIZ is important for the retention of 
G9a on chromatin.  Using pharmacological 
inhibition of G9a, and gene silencing methods to 
regulate WIZ, we compared G9a localization with 
evidence of enzymatic activity. Although loss of 
G9a chromatin localization mediated by WIZ and 
small molecule inhibition of G9a and GLP activity 
(30) both result in loss of H3K9me2, these 
treatments variably affect gene expression and 
G9a protein-interacting partners.  
 
Experimental Procedures 
Cell culture - HEK 293T cells were grown 
in DMEM supplemented with 10% fetal bovine 
serum (FBS).  FLAG-HA-G9a HeLa cells (9) were 
grown in MEM supplemented with 5% FBS and 
5% Horse Serum.  Stable pools of WIZ shRNA 
knockdown and control shRNA knockdown cells 
were created as follows: FLAG-HA-G9a HeLa 
cells (9) were transduced with lentivirus 
containing WIZ shRNA with a target sequence 
identical to the WIZ siRNA used in this study 
(Sigma Mission WIZ #SHCLNV; clone ID 
TRCN0000253784) or a control shRNA that 
contains an shRNA insert that does not target any 
known genes from any species (Sigma Mission 
pLKO.1-puro Non-Target shRNA #SHC016V).  
Transduced cells were selected with 5 µg/mL 
puromycin, and the resulting stable pools were 
grown in MEM supplemented with 5% FBS, 5% 
horse serum, and 5 µg/mL puromycin. 
WIZ cloning - WIZ cDNA (Thermo Fisher 
Scientific #MH51768-101549168) was PCR 
amplified with o-WIZclone-1 (forward, 5’-
GGGTCTAGAGATGGTGGCCATGGACTTGG
G-3’) and o-WIZclone-2 (reverse, 5’-
GCGCCGCGGGGGAGCCTCTGCCGCCGCTG-
3’), and cloned into pcDNA™3.1/myc-His B 
(Invitrogen #V855-20) with Xba I and Sac II.   
siRNA knockdown and compound 
treatment - Cells were treated with the indicated 
media supplemented with 1 µM UNC0638 (30) or 
the volume equivalent of DMSO for 48 hours or 
96 hours as indicated.  All siRNAs were purchased 
from Dharmacon (GE), and transfections were 
performed as per manufacturer’s instructions with 
DharmaFECT 4 transfection reagent.  siRNAs 
used in this study were as follows: Control 
(scrambled) siRNA (Dharmacon Non-targeting 
#001810-04), G9a siRNA (Dharmacon #006937-
05), wiz siRNA custom (ON-TARGETplus 
Dharmacon) sense sequence: 5’-
CAGCAGAGGUCAAGGCCAAUU-3’; and 
antisense sequence: 5’-
UUGGCCUUUGACCUCUGCUGUU-3’. 
Quantitative RT-PCR - RNA was 
extracted using the RNeasy Plus Mini Kit 
(Qiagen) and RNA was quantified on the 
NanoDrop 2000 spectrophotometer (Thermo 
Fisher Scientific).  The reverse transcription 
reaction was performed with 500 ng RNA and the 
Superscript III First Strand Synthesis Supermix 
(Invitrogen #1172-050) according to manufacturer 
instructions.  The resulting cDNA was diluted 1:10, 
and 2 µL was used for each PCR reaction.  
Quantitative PCR was performed using Roche 
FastStart Universal SYBR Green Master Mix 
(Rox) in a 384-well plate format on the ABI 
2900HT instrument.  Oligo sequences are 
available upon request. 
Immunoprecipitation - Whole cell protein 
extract was prepared by lysing cells in 
Cytobuster™ Protein Extraction Reagent (EMD 
Millipore #71009) supplemented with 25U 
Benzonase Nuclease (EMD Millipore #101654).  
Subcellular fractionation was performed using the 
Pierce Subcellular Fractionation Kit (Thermo 
Fisher Scientific #78840) according to 
manufacturer’s instructions.  FLAG-HA-G9a was 
immunoprecipitated from the samples described 
with Anti-FLAG® M2 Affinity Gel (Sigma 
#A2220) overnight at 4°C, and washed three times 
in TBST (20 mM Tris-HCl, pH 8.0, 150 mM NaCl, 
0.1% TWEEN-20).  Bound proteins were eluted 
by boiling in 1X SDS PAGE loading buffer, and 
subjected to western blot analysis.   
G9a protein stability assay - FLAG-HA-
G9a cells were plated on 6-well plates at a density 
of 5x105 cells/well.  After 24 hours, cells were 
transfected with siRNA as previously described, or 
treated with 1 µM UNC0638 (or volume 
equivalent of DMSO), and incubated for 48 hours.  
Cells were then treated with 1 µM MG132 (or 
volume equivalent of DMSO) for 12 hours, 
followed by the addition of 25 µg/mL (Fig. 3A), or 
50 µg/mL (Fig. 3B) cycloheximide (or volume 
equivalent of ethanol) for 0, 4, 6, 9, or 13.5 hours.  
Cells were lysed in Cytobuster™ Protein 
Extraction Reagent (EMD Millipore #71009) 
supplemented with 25U Benzonase Nuclease 
(EMD Millipore #101654).  Protein extract 
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concentration was determined with Bradford 
reagent (Bio-Rad #500-0006) and a standard curve 
generated by known quantities of bovine serum 
albumin.  Ten µg of lysate was run on an SDS 
PAGE gel and subjected to western blotting. 
Western Blotting - Western blotting was 
performed using a Typhoon imager (GE) as 
described in (31), or using a LI-COR Odyssey as 
described in (32).  Densitometry was performed 
using Image J software, or LI-COR Image Studio 
software.   
Chromatin Immunoprecipitation - 
Chromatin immunoprecipitation was performed 
using the ChIP-IT High Sensitivity kit (Active 
Motif #53040) according to manufacturer’s 
instructions except that Input samples were 
purified by phenol:chloroform extraction.  The 
following antibodies were used: anti-H3K9me2 
(Abcam #ab1220), anti-H3K9me3 (Abcam 
#ab8898), anti-G9a (Abcam #ab40542), and 
Rabbit IgG (Jackson Immunoresearch #011-000-
003).  ChIP samples were quantitated using the 
Qubit 2.0 Fluorometer (Invitrogen).  A portion of 
each sample was confirmed by qPCR as described 
above.  Fold change over background was 
calculated using the ΔΔCt method (33) where 
IP/Input for the ChIP antibody signal was 
compared to the IP/Input value for IgG 
(background).  After confirmation of a ChIP signal 
over background, the remainder of the sample was 
submitted for high throughput sequencing.  Oligo 
sequences are available upon request. 
High-throughput sequencing and data 
analysis - Libraries were prepared for high-
throughput using the Illumina TruSeq kit as per 
manufacturer’s recommendations. Single-end 
50bp reads were sequenced on an Illumina HiSeq. 
Reads were checked to be of sufficient quality, 
filtered to remove those with significant adapter 
contribution using TagDust (34), and aligned to 
the reference human genome (hg19) using Bowtie 
(35). Regions of significant ChIP enrichment 
relative to input control (“peaks”) were identified 
using MACS2 assuming fragments were 250bp in 
length. Heatmaps were generated in MATLAB by 
plotting the normalized ChIP-seq signal around the 
midpoints (+/- 2kb) of the union set of G9a peaks. 
Changes in ChIP signal were illustrated by taking 
the arithmetic difference between treated and 
untreated samples.  ChIP-seq data is available 
from NCBI GEO (GSE67317).  Genomic 
distributions were computed using CEAS (36). 
CTCF and H3K4me3 ChIP-seq data from 293T 
cells were mined from BAM files provided by 
ENCODE (37). To find regions with significantly 
altered ChIP-seq enrichment, the number of 
overlapping aligned reads for all 500 bp non-
overlapping windows across the genome was first 
tabulated for all samples. Only those windows 
with an average number of aligned reads 
exceeding 10 were retained. A binomial test was 
then applied to compare G9a ChIP-seq signal 
between control siRNA-treated and WIZ siRNA-
treated cells at each of these windows; p-values 
were corrected for multiple testing using the q-
value. Windows with q < 1 x 10-5 were retained 
and used for subsequent analyses.  
Gene expression microarrays - RNA was 
extracted using the RNeasy Plus Mini Kit 
(Qiagen), and quantified on the Qubit Fluorometer 
(Invitrogen).  RNA quality was verified on the 
Agilent Bioanalyzer before hybridization to 
Human 8x60K arrays (Agilent #28004).  After 
scanning, microarray images were processed using 
Agilent Feature Extractor according to 
manufacturer-supplied protocols.  The resulting 
background subtracted and loess normalized log 
ratio data were collected and filtered to remove 
data generated from poor quality or low intensity 
spots.  Probes with >30% missing data were 
removed from further evaluation. Dye swap 
replicates were inverted to match the log ratio 
direction of non-dye swap replicates. Remaining 
missing data were then imputed using k-NN 
imputation (38). Testing for differential expression 
was performed using the Statistical Analysis of 
Microarray (SAM) (39) one-class option for 
comparison to DMSO or scrambled siRNA control, 
and the two-class unpaired option when comparing 
UNC0638 to WIZ siRNA knockdown.  A 
conservative false discovery rate threshold of 
0.5% was set to identify differentially expressed 
genes in both experiments.  Differential expression 
results were visualized using hierarchical cluster 
analysis based on average linkage clustering and a 
Pearson correlation distance metric. All statistical 
analyses were carried out using the R package 
(v3.1.1).  Expression data is available from NCBI 
GEO (GSE70914). 
G9a purification for proteomics - G9a was 
purified from the HeLa FLAG-HA-G9a cell line 
(9) grown in a volume of 5 liters (~8 mL cell 
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pellet), treated with either 1 µM UNC0638 or 
volume equivalent of DMSO for 48 hours.  Cells 
were centrifuged, washed once in phosphate 
buffered saline (PBS), then frozen at -80°C prior 
to purification.  Purification was performed as 
follows.  All buffers were supplemented with 1X 
protease inhibitor cocktail (Roche #05056489001).  
Cell pellets were thawed on ice, then resuspended 
in 40 mL Nuclei Prep Buffer (50% glycerol; 0.5% 
NP-40; 1 mM PMSF; 10 mM Tris-HCl, pH 7.4; 10 
mM NaCl; 3 mM MgCl2), and incubated on ice for 
10 minutes or until nuclei were visible with trypan 
blue stain.  Nuclei were pelleted, washed once 
with RSB (10 mM Tris-HCl, pH 7.4; 10 mM 
NaCl; 3 mM MgCl2), then resuspended in 24 mL 
Nuclei Lysis Buffer (0.2% Triton-X-100; 20 mM 
HEPES, pH 7.9; 1.5 mM MgCl2; 0.56 M NaCl; 10 
mM KCl; 0.5 mM DTT), supplemented with 250U 
Benzonase Nuclease (EMD Millipore #101654), 
and incubated at 37°C for 10 minutes, followed by 
1 hour at 4°C.  Nuclear lysate was clarified by 
ultracentrifugation for 30 minutes at 40,000 rpm in 
a Ti70.1 rotor, salt concentration lowered from 
~0.42M to ~0.3M with No salt Nuclei Lysis 
Buffer (10 mM HEPES, pH 7.9; 1.5 mM MgCl2; 
10 mM KCl; 0.5 mM DTT), followed by 
ultracentrifugation as described above.  Lysate 
was transferred to a chromatography column (Bio-
Rad #731-1550), and Anti-FLAG® M2 Affinity 
Gel (Sigma #A2220) equilibrated in 0.42M NaCl 
Nuclei Lysis Buffer (~100 µL beads) was 
incubated with the clarified lysate overnight at 4°C. 
Beads were washed with 50 mL Wash Buffer 
(0.2% Triton-X-100; 10 mM HEPES, pH 7.9; 1.5 
mM MgCl2; 0.3 M NaCl; 10 mM KCl), and 
transferred to a 0.8 mL chromatography spin 
column (Pierce #89868), protein was eluted by 
rotation at room temperature 200 µL Elution 
Buffer (50 mM Tris-HCl, pH 7.5; 0.5% NP-40; 
0.15 M NaCl; 0.2 mg/mL 2xFLAG peptide), 3 
times for a total of ~600 µL of eluate.  Eluates 
were diluted to 1.5 mL final volume in Wash 
Buffer and transferred to a chromatography 
column (Bio-Rad #732-6008).  Anti-HA agarose 
(Sigma #A2095) was equilibrated in Wash Buffer 
(~100 µL beads) and incubated with the eluates 
overnight at 4°C.  Beads were washed with 30 mL 
wash buffer, and then transferred to a 0.8 mL 
chromatography spin column (Pierce #89868).  
Proteins were eluted 200 µL Elution Buffer (50 
mM Tris-HCl, pH 7.5; 0.5% NP-40; 0.15 M NaCl; 
1.0 mg/mL HA peptide), 4 times for a total of 
~800 µL of eluate.  A portion of the eluates was 
visualized by silver staining and the remaining 
sample was submitted for mass spectrometry 
analysis. 
Proteomic analysis - Multidimensional 
protein identification technology (MudPIT) was 
carried out as previously described (40,41).  In 
brief, proteins from each elution were precipitated 
with tricholoroacetic acid and the resulting pellets 
were washed with 100% cold acetone.  Dried 
protein pellets were then resuspended in 8M urea 
and reduced and alkylated with tris(2-
carboxyethyl)phosphine and chloroacetamide as 
previously described (42). The proteins were then 
subjected to proteolytic digestion with LysC 
overnight at 37°C with shaking followed by 
digestion with Trypsin Gold (Promega) after 
diluting the sample to 2M urea. The reaction was 
quenched with formic acid and then pressure 
loaded onto a microcapillary column pack with 
both strong cation exchange resin and reverse 
phase resin as previously described (42). A 9-step 
MudPIT run was performed for each sample on an 
LTQ-Velos Pro that was in-line with a Proxeon 
Easy nanoLC (41).  The resulting RAW data files 
were processed by protein database matching 
using SEQUEST within Proteome Discoverer 1.4 
(Thermo). Database matching was performed 
using a Homo sapiens FASTA database 
downloaded from Uniprot on 03/16/2014. The 
database also contained potential sample 
contaminant proteins including human keratins, 
IgGs, and proteolytic enzymes. Database search 
was performed with +57 daltons on cysteine as a 
static modification and the following 
modifications as dynamic: +16 dalton on 
methionine (oxidation), +14 dalton on lysine 
(mono-methylation), +28 dalton on lysine (di-
methylation), and +42 dalton on lysine (tri-
methylation). All peptide-spectral matches (PSMs) 
were required to have a false discovery rate of ≤ 
1%. SAINT (Significance analysis of interactome) 
probability scores were calculated as outlined in 
the Contaminant Repository for Affinity 
Purification (CRAPome) and various previous 
publications (41,43-45). Mock purifications were 
performed in parallel in this study and analysis 
using the same methods described above for 
SAINT analysis.  
 
 at Indiana U
niversity School of M
edicine on D
ecem
ber 15, 2016
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
WIZ Regulates Retention of G9a on Chromatin 
	   6	  
Results 
Enzymatic inhibition of G9a or 
knockdown of WIZ expression leads to a global 
reduction in H3K9 methylation levels - We 
initially compared H3K9me2 levels following 
chemical inhibition of G9a catalytic activity and 
reduction in G9a protein levels due to WIZ 
knockdown.  Inhibition of G9a catalytic activity in 
HEK293T cells with a small molecule probe, 
UNC0638 (30) did not result in a change in G9a, 
GLP or WIZ mRNA levels (Fig. 1A), but did lead 
to a global reduction in H3K9me2 levels and an 
increase in G9a protein (Fig. 1B-C).  Treatment of 
HEK293T cells with a siRNA against WIZ 
reduced WIZ mRNA 5-fold (p < 0.0001), but did 
not affect G9a or GLP mRNA levels (Fig. 1D). 
H3K9me2 (p = 0.03), and WIZ (p = 0.001) protein 
levels decreased compared to the control siRNA 
(Fig. 1E-F).  There was also a slight (1.25-fold) 
decrease in G9a levels, which agrees with a 
previous study that linked WIZ with G9a protein 
stability (29). To determine if WIZ knockdown 
affects long-term G9a protein stability, we stably 
expressed WIZ shRNA or control in a HeLa cell 
line that expresses a double tagged version of G9a 
(9).  These cells demonstrated no change in G9a or 
GLP mRNA levels (p = 0.1311), whereas WIZ 
mRNA levels were reduced 2-fold (p = 0.035) (Fig. 
1G).  Even after multiple passages of this cell line, 
the overall change in G9a protein levels remained 
very small (1.25-fold, p = 0.02), while H3K9me2 
levels were reduced 2.5-fold (p = 0.01) and WIZ 
protein levels were 2.5-fold lower (Input, p = 0.02) 
(Fig. 1H-I).  These data suggest that reduction in 
H3K9me2 associated with WIZ silencing was not 
due to progressive loss of G9a protein.   
WIZ is important for G9a interaction with 
chromatin - Since other zinc finger proteins have 
been shown to regulate KMT activity (46,47) we 
investigated the possibility that WIZ is important 
for G9a retention on chromatin.  To assess G9a 
chromatin interaction, we performed subcellular 
fractionation of HEK293T cells that were treated 
with UNC0638, WIZ siRNA, or combinations of 
the two to determine if these treatments had an 
additive effect. Neither treatment nor the 
combination had an effect on G9a or GLP mRNA 
levels, while WIZ mRNA levels were reduced to a 
similar extent in both the siRNA knockdown and 
the combination treatment (Fig. 2A). H3K9me2 
levels were visibly reduced after treatment with 
UNC0638 in combination with control siRNA (Fig. 
2B, compare lane 5 to lane 6, 4.8-fold), or WIZ 
siRNA (Fig. 2B, compare lane 5 to lane 8, 8.6-
fold), and slightly reduced after treatment with 
DMSO combined with WIZ siRNA (Fig. 2B, 
compare lane 5 to lane 7, 1.6-fold).  Consistent 
with the changes in H3K9me2 levels, G9a and 
GLP association with the chromatin fraction was 
altered after treatment with UNC0638 or WIZ 
siRNA.  G9a levels decreased slightly after 
addition of UNC0638 (Fig. 2B, compare lane 5 
and lane 6, 1.9-fold), WIZ siRNA (Fig. 2B, 
compare lane 5 and lane 7, 1.8-fold), or a 
combination of both treatments (Fig. 2B, compare 
lane 5 and lane 8, 6.2-fold).  Similar to G9a, GLP 
levels decreased in the chromatin fraction after 
addition of UNC0638 (Fig. 2B, compare lane 5 
and lane 6, 1.9-fold), WIZ siRNA (Fig. 2B, 
compare lane 5 and lane 7, 1.7-fold), or a 
combination of both treatments (Fig. 2B, lane 5 
compared to lane 8, 9.1-fold).  The dramatic 
reduction in G9a and GLP protein levels in the 
chromatin fraction after the combination 
treatments (Fig. 2B, lane 8) indicates that 
enzymatic inhibition and reduction in WIZ protein 
levels have an additive effect, and suggests that 
WIZ may help stabilize G9a interaction with 
chromatin.   
Since we observed increased G9a in the 
soluble fraction after UNC0638 treatment not 
attributable to an increase in G9a mRNA (Fig. 1A 
and Fig. 2A), we examined G9a protein stability in 
HeLa FLAG-HA-G9a cells. We inhibited de novo 
protein synthesis with cycloheximide (CHX) in 
combination with MG132, a proteasome inhibitor, 
UNC0638, or WIZ siRNA knockdown (Fig. 3).  
Although treatment with UNC0638 for 48 hours 
resulted in higher levels of G9a, none of the 
treatments demonstrated diminished G9a protein 
turnover including up to 13.5 hours CHX 
treatment (Fig. 3A).  As a control, levels of a 
control protein, COXIV, were reduced after 6 
hours of CHX treatment (Fig. 3B).  Extending the 
experiment beyond 13.5 hours was not possible 
(Fig. 3A) due to cell toxicity.  Thus, we cannot 
rule out the possibility that UNC0638 increases 
long-term G9a protein stability. 
To further examine G9a association with 
chromatin, we performed subcellular fractionation 
of HeLa cells expressing FLAG-HA-tagged G9a, 
followed by FLAG immunoprecipitation (IP) of 
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G9a.  G9a association with GLP, WIZ, H3K9me3, 
or H3 does not change following UNC0638 
treatment (Fig. 4A-B), but H3K9me2 levels in 
three biological replicate experiments are lower in 
the input (p = 0.030) and IP (p = 0.001) samples 
compared to H3 input signal (Fig. 4B).  We 
repeated the experiment using a FLAG-HA-G9a 
HeLa stable pool expressing a control, or WIZ 
shRNA knockdown (Fig. 4C).  Although G9a 
continued to interact with GLP when WIZ was 
knocked down, its interaction with both K9 di- 
(2.2-fold) and tri-methyl (2.3-fold) H3 and total 
H3 (2.2-fold) was noticeably reduced.  These data 
indicate that reduction in WIZ protein levels 
decreases the association of G9a with histones in 
the chromatin fraction (Fig 4D).  We then 
examined G9a and WIZ localization to either the 
nuclear or chromatin fractions (equivalent to Fig. 
4A, 4C input).  Treatment with UNC0638 resulted 
in an increase in G9a protein levels in the nuclear 
compartment as noted earlier (Fig. 2B), but G9a 
levels remained unchanged in the chromatin 
fraction and no alteration in WIZ protein levels 
was observed (Fig. 4E).  In contrast, WIZ shRNA 
knockdown significantly reduced G9a levels in the 
chromatin fraction (Fig. 4F, 2-fold).  
To confirm that this effect was WIZ-
specific, we transfected a plasmid expressing the 
short human WIZ splice variant cDNA into the 
stable WIZ silenced HeLa cells from (Figure 1E), 
followed by subcellular fractionation (Fig. 5).  The 
short isoform (WIZS) was selected for 
reconstitution for several reasons.  First, it 
contains five zinc fingers that are highly conserved 
in mouse and human WIZ, whereas the additional 
zinc fingers present the long isoform (WIZL) are 
less conserved (26,48).  Second, in mice, WizL and 
WizS are expressed at different times during 
development, with WizS being highly expressed in 
the developing cerebellum, and WizL expression 
restricted to the mature cerebellum (26).  Despite 
disruption of WizL in C57BL/6 mice due to the 
insertion of an ETn retrotransposon, there is no 
obvious phenotype in the cerebellum, suggesting a 
nonessential role for WizL (48).  Third, G9a and 
GLP interact with the C-terminal zinc finger of 
WIZ, which is present in the protein product for 
both splice variants (29).  Note that the WIZ 
siRNA recognizes the 3’-end of the WIZ transcript 
and therefore both isoforms were knocked down 
after treatment (Fig. 5A).  Since WIZ mRNA was 
reduced about 2-fold in the shRNA stable cell line 
(Fig. 1E), and the pWIZ vector was overexpressed 
compared to endogenous WIZ (data not shown), 
we did not mutate the region targeted by WIZ 
shRNA in the pWIZ vector.   
In the WIZ knockdown pool, G9a protein 
levels were reduced in the chromatin fraction 
compared to the control knockdown pool (p = 
0.024, Figs. 5B-C).  Transfection of the pWIZ 
vector resulted in an increase in G9a protein levels 
in the chromatin fraction to levels comparable to 
those of the control knockdown pool (p = 0.028, 
Figs. 5B-C).  Thus, the protein product of the 
WIZS isoform is sufficient to restore G9a and WIZ 
protein levels to chromatin. 
 To determine if G9a chromatin occupancy 
was affected by enzymatic inhibition or reduced 
levels of WIZ, we performed chromatin 
immunoprecipitation followed by high-throughput 
sequencing (ChIP-seq).  HEK293T cells were 
treated with 1 µM UNC0638 or DMSO for 48 (Fig. 
6A) or 96 hours (Fig. 6B), or control siRNA or 
WIZ siRNA for 72 hours (Fig. 6C), followed by 
ChIP with antibodies against G9a or H3K9me2 
(30) (Figs. 6-8). 
We first normalized the ChIP-seq 
enrichment computed over the union set of G9a 
binding sites to account for differences in 
sequencing depth. We then assessed the difference 
in G9a and H3K9me2 ChIP-seq signal between 
UNC0638- (Figs. 6A-B) or WIZ siRNA- (Fig. 6C) 
treated and untreated cells by subtracting the 
signal from control cells.  A reduction in 
H3K9me2 signal was observed for all treated 
samples compared to controls (Figs. 6A-C, 6E).  
Following UNC0638-treatment, the G9a signal 
was elevated (Figs. 6A-B, 6D), which might be 
explained by the increase in G9a protein levels 
(Figs. 2B, 3, 4A).  This elevation in G9a signal 
was general and subtle, with no one site in 
UNC0638-treated samples having a statistically 
significant increase over controls. The signal 
difference decreased and became more diffuse 
after 96 hours.  In contrast, WIZ siRNA treatment 
resulted in a loss of G9a signal (Figs. 6C-D).  
Examples of changes at specific regions are 
highlighted (Figs. 7A-C).  These data suggest that 
decreased G9a chromatin binding associated with 
reduction in WIZ is responsible for the loss of 
H3K9me2.  
 at Indiana U
niversity School of M
edicine on D
ecem
ber 15, 2016
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
WIZ Regulates Retention of G9a on Chromatin 
	   8	  
Assessment of the genomic distribution of 
regions with G9a occupancy revealed that the 
majority of G9a signal was localized to introns or 
distal intergenic regions (Fig. 8A).  UNC0638 
treatment resulted in a slight increase in G9a 
occupancy at distal intergenic regions at 48 hours 
(2.8%) and 96 hours (4%), with no other large 
changes in occupancy distribution noted.  
Treatment with WIZ siRNA had little effect on 
overall G9a distribution with remaining G9a signal 
increasing slightly at promoters (1.6%) and 
decreasing slightly at distal intergenic regions 
(2.7%).  Since WIZ siRNA knockdown resulted in 
overall loss of G9a signal, we examined the 
genomic distribution of regions with reduced G9a 
occupancy compared to control siRNA 
knockdown (Fig. 8B).  We identified 14,116 
regions where G9a occupancy was significantly 
reduced following WIZ knockdown (binomial test, 
q < 1 x 10-5).  Many of these differential regions 
were distal from genes.  ~83% of these sites were 
greater than 10 kilobases (Kb) from a transcription 
start site (TSS), and the median distance to the 
nearest TSS was ~30 Kb.  There were, however, 
2,389 sites within 10 Kb of a TSS.  Despite the 
small proportion of sites (~17%) in the vicinity of 
a TSS, we noted that the loss of G9a was slightly 
skewed toward promoters and coding exons 
following WIZ siRNA treatment relative to the 
genomic coverage of those features.  Associating 
sites of G9a signal loss with ENCODE ChIP data 
for HEK293 cells (37), we observed signal 
enrichment with H3K4me3 and the CCCTC-
Binding Factor (CTCF) (Fig. 8C), which are 
associated with active transcription.  
The effects on gene expression by WIZ 
knockdown do not completely overlap with those 
by enzymatic inhibition of G9a - Since WIZ 
silencing and G9a inhibition both led to reduced 
H3K9me2 levels, we asked whether gene 
expression is similarly affected.  G9a can act as 
both a co-activator and co-repressor of 
transcription (49-53).  As the ability of G9a to 
affect transcription is not fully dependent on its 
catalytic activity we predicted that treatment with 
UNC0638 would have a different effect on global 
gene expression compared to WIZ knockdown.  
Microarray-based gene expression 
analysis was performed using cDNA from 
HEK293T cells treated with G9a siRNA, WIZ 
siRNA, or UNC0638 (Fig. 9) and compared to 
cDNA from control siRNA knockdown or vehicle 
(DMSO) treatment.  We identified genes that 
demonstrated a concordant (Fig. 10A) or divergent 
(Fig. 10B) change in gene expression.  Gene 
expression was median centered to highlight the 
magnitude of differential expression. 
For genes with a similar trend in RNA 
abundance after either WIZ knockdown or 
UNC0638 treatment (Fig. 10A), 72% (147/205 at 
<0.5% false discovery rate (FDR)) exhibited lower 
expression, suggesting a significant effect of these 
treatments on G9a co-activator function.  In 
comparison, G9a knockdown resulted in a 50% 
overall gene repression (135/205 genes).  Since 
loss of G9a protein results in degradation of GLP 
as well as loss of the proteins that would normally 
interact with the heterodimer (13,25), it is not 
surprising that G9a knockdown affects gene 
expression differently than either enzymatic 
inhibition (UNC0638 treatment) or loss of 
chromatin association (WIZ knockdown).  Indeed, 
this observation is also true for genes with 
divergent expression changes following WIZ 
knockdown versus UNC0638 treatment (Fig. 10B). 
For differentially expressed genes (Fig. 
10B, 118 genes at < 0.5% FDR), enzymatic 
inhibition resulted in de-repression of gene 
expression, while WIZ knockdown led to 
transcriptional repression.  As noted earlier, only 
~17% of regions of G9a loss were within 10 Kb of 
a TSS.  Of these sites, 42% (1,015) were near a 
gene that was represented on our microarray.  
Though only 32 of those regions were near a gene 
with a significant (q < 0.05) change in gene 
expression (Fig. 10C), all but one of those genes 
were repressed following WIZ knockdown.  In 
contrast, UNC0638 treatment showed less overall 
change in gene expression profiles in the same 
regions.  The fact that loss of G9a ChIP signal 
after WIZ knockdown is associated with signals 
associated with active transcription, but are not 
generally seen directly at transcription start sites 
(Figs. 8B-C), could indicate that G9a exerts co-
transcriptional influence from a distance. 
  Taken together, these data suggest that 
binding of G9a to chromatin is important for its 
role as a co-activator, whereas enzymatic activity 
is associated with co-repressor function.  These 
observations are consistent with the promoter and 
exon-skewed loss of G9a following siRNA WIZ 
knockdown (Figs. 8B-C), and with prior studies 
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indicating that G9a catalytic activity is dispensable 
for co-activator function (49,50,52-54).   
Enzymatic inhibition with UNC0638 and 
WIZ knockdown differentially affect the 
interaction of G9a with its protein-binding 
partners – Based on the observation that WIZ-
mediated loss of G9a association with chromatin 
had different consequences for gene expression 
compared to enzymatic inhibition, we predicted 
that G9a protein-protein interactions would also be 
differentially affected.  To determine how 
enzymatic inhibition of G9a compares to WIZ 
knockdown, FLAG-HA-tagged G9a (9) was 
tandem affinity purified from HeLa cells treated 
with UNC0638 or DMSO (Fig. 11A), or cells from 
the stable control or WIZ knockdown pools (Fig. 
11B), and subjected to mass spectrometry analysis.  
Significant G9a-associated proteins were 
determined using the SAINT (significance 
analysis of interactome (44)) scoring method (Fig. 
12A).  Both known and novel associations with 
prey protein were identified.  Enzymatic inhibition 
of G9a had a greater effect on protein association 
compared to WIZ knockdown (Fig. 12B).  
Differences could be due to the fact that there was 
only about a 40% reduction in WIZ protein levels 
in the knockdown cells compared to the control, 
whereas UNC0638 treatment at 1 mM results in 
>90% inhibition of catalytic function (30).  
Alternatively, in the absence of WIZ, G9a may 
retain catalytic activity toward non-histone 
substrates.  
  
Discussion   
 We demonstrated that WIZ is important 
for G9a interaction with chromatin.  Stable 
knockdown of WIZ reduced H3K9me2 levels and 
resulted in a very slight reduction in G9a protein 
levels that remained stable over time (Fig. 1G-I).  
This WIZ-mediated effect was specific, because 
reconstitution of exogenously expressed WIZ into 
WIZ knockdown cells increased G9a chromatin-
associated protein (Figs. 5B-C), and global, since 
WIZ knockdown resulted in a dramatic loss of G9a 
occupancy on chromatin (Fig 6). 
The WIZ protein contains C2H2-type zinc 
finger motifs that have an unusually widely spaced 
configuration (26).  In Petunia, the EPF family of 
proteins has two widely separated C2H2 zinc 
fingers that recognize and bind to specific DNA 
sequences (55-57).  Drosophila proteins with 
widely spaced zinc finger motifs include the 
chromatin-associated suppressor of variegation 3-7 
(58-60), and the homeotic protein, Teashirt, which 
binds sequence-specific gene regulatory sites in 
vitro (61), and behaves as a transcriptional 
repressor when transfected into human cells (62).  
The murine orthologues of Teashirt also act as 
transcriptional repressors and are involved in 
developmental roles similar to the fly Teashirt 
(63,64).  Thus, despite an unusual configuration, 
proteins with widely spaced zinc finger motifs are 
compatible with DNA binding and transcriptional 
regulation.  This conclusion was further supported 
by findings published while our manuscript was 
being prepared for submission (65).  
Co-transcriptional activity of G9a - 
Although both loss of WIZ and small molecule 
inhibition of G9a reduced H3K9me2 levels, they 
appeared to do so by distinct mechanisms.  
UNC0638 binds in the substrate-binding site of 
G9a, and is noncompetitive with the cofactor S-
adenosyl-L-methionine (SAM) (30).  Yet, while 
UNC0638 treatment effectively decreased cellular 
H3K9me2 levels, it did not generally displace G9a 
from chromatin.  In contrast, silencing the G9a 
complex member, WIZ, resulted in loss of both 
G9a occupancy on chromatin (Figs. 6-7).   
The power of a combinatorial approach to 
study G9a signaling was highlighted by 
differential gene expression analysis, which 
suggested that G9a catalytic activity was 
associated with co-repressor function, while G9a 
occupancy on chromatin was more closely related 
to its function as a co-activator (Fig. 10B).  The 
G9a catalytic domain is sufficient for silencing a 
target reporter gene (66,67), however, G9a 
promotes DNA methylation through its ankyrin 
repeat domain independent of its lysine 
methylation activity (13,68-71).  Furthermore, the 
catalytic activity of G9a is dispensable for 
transcriptional activation of several genes 
(49,50,52-54), and G9a has a number of non-
histone substrates, including itself, which would 
be affected by enzymatic inhibition, but 
potentially not a knockdown of WIZ (17-21).  Our 
results confirmed that catalytic activity was 
dispensable for the regulation of a subset of genes 
on our microarray (Fig. 10B).  Comparison of 
either UNC0638-treatment or WIZ siRNA 
knockdown to a G9a siRNA knockdown would 
not have revealed this stark contrast since loss of 
 at Indiana U
niversity School of M
edicine on D
ecem
ber 15, 2016
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
WIZ Regulates Retention of G9a on Chromatin 
	   10	  
G9a produced a gene expression pattern that 
overlapped with both treatment conditions (Fig 
10B). 
Our ChIP-seq data showed that G9a loss 
occurred mainly at distal intergenic and intronic 
regions of the genome (Fig. 8B), however, sites of 
signal were slightly skewed towards promoters 
and coding exons.  Sites of G9a loss also 
overlapped with sites of H3K4me3 and CTCF-
binding (Fig. 8C).  These data were consistent 
with our gene expression analysis, which 
associated G9a occupancy on chromatin with its 
co-activator activity at a subset of genes (Fig. 
10B). 
Despite the strong association between 
G9a occupancy and transcriptional activity, we 
noted that overall median distance of sites of G9a 
loss following WIZ siRNA knockdown to the 
nearest TSS was ~30 Kb (Fig. 8B).  In addition, 
the majority of sites occupied by G9a were located 
in distal intergenic regions (Fig. 8A).  These 
findings suggested that G9a co-transcriptional 
activity in HEK293T cells was mostly exerted at a 
significant distance from the site of transcription 
initiation.  The H3K9me2 mark is unique 
compared to some other histone modifications due 
to broad regional deposition (72).  It has been 
proposed that G9a target specificity is determined 
by multiple interactions with chromatin or 
sequence-specific DNA binding molecules (6,8).  
It would be interesting to determine if G9a binding 
mediates chromatin looping to allow its interaction 
with multiple sites in the genome from a localized 
domain.   
G9a protein-interacting partners - The 
loss of H3K9me2 by two distinct mechanisms 
allowed for comparison of the genomic and 
proteomic differences resulting from either 
enzymatic inhibition or re-localization of G9a.  
Proteomic data suggested that interaction of G9a 
with its non-histone targets was affected by 
enzymatic inhibition to a greater extent than 
reduction of WIZ and chromatin targeting (Fig. 
12).  As expected, GLP and WIZ were identified 
as significantly interacting proteins (SAINT ≥ 0.9).  
Additional known G9a-associated proteins 
included: chromodomain on Y-like 1 (CDYL1) 
(73,74), which binds methylated H3K9, histone 
deacetylase 1 (HDAC1) and HDAC2 (75), 
mesoderm induction early response 1 (MIER1) 
(76), which represses transcription through 
recruitment of HDAC1, and chromobox homolog 
(CBX1, or heterochromatin protein beta (HP1β)), 
and CBX3 (HP1γ) (77-80), readers of methylated 
H3K9.  Mass spectrometry analysis by others has 
shown that many of these proteins interact to form 
complexes.  CDYL1 bridges the REST repressor 
and G9a to regulate neuronal gene expression.  In 
addition to G9a and GLP, CDYL1 co-purified 
with WIZ, HDAC1 and HDAC2, and MIER1 (81).  
HDAC2 was shown by mass spectrometry to 
associate with G9a, GLP, WIZ, MIER1 and 
MIER2, while the reciprocal purification with G9a 
bait yielded both HDAC2 and MIER1 (82).   
 We noted that enzymatic inhibition of G9a 
had more effect on its protein interacting partners 
compared to WIZ knockdown (Fig. 12B).  These 
data could be a result of an inefficient WIZ 
knockdown (WIZ protein levels were reduced by 
~40%), or they could indicate that G9a displaced 
from chromatin maintains catalytic activity toward 
non-histone substrates.  In support of the latter 
interpretation, proteins with the largest abundance 
changes in UNC0638-treated cells compared to 
controls were non-histone substrates, or closely 
associated with non-histone substrates of G9a.  
Automethylation of G9a was shown to be 
important for its interaction with CBX3 (17,19,67).  
Other non-histone substrate protein interactions 
that were reduced following treatment included 
CDYL1, HDAC1, GLP, and WIZ (18,21).  
Knockdown of WIZ did not result in a change in 
association of G9a with CDYL1 or CDYL2, again 
implying that G9a enzymatic activity is important 
for this interaction.  Other associations that were 
affected by enzymatic inhibition, but not WIZ 
knockdown include CBX1 and ZNF644.  These 
data suggest that methylation of non-histone 
substrates by G9a could be important for 
maintaining interactions with various protein 
complexes. 
Overall, our findings underscore the 
potential of combining small molecule probes with 
gene silencing to dissect molecular pathways.  
Understanding the mechanistic basis for 
differences between pharmacologic and genetic 
manipulations is essential to any translational 
hypotheses related to G9a function (83-85).
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Figure Legends 
 
Figure 1.  Treatment with UNC0638 and knockdown of WIZ results in loss of H3K9me2.  (A) RT- 
qPCR of G9a, GLP, and WIZ mRNA expression in HEK293T cells treated with UNC0638 or vehicle 
control for 48 hours, normalized to B2M expression.  Error bars represent the standard deviation of three 
biological replicates.  (B) Western blots of whole cell extract (WCE) from HEK293T cells treated with 1, 
2, and 4 µM UNC0638 or vehicle control for 48 hours. (C) Densitometry of western blot bands 
represented by Fig. 1B.  Error bars represent the standard deviation of three biological replicates. X-axis 
shows the G9a and H3K9me2 signals.  Y-axis shows the fold change in densitometry signal after 1 µM 
UNC0638 treatment relative to DMSO.  P-values are indicated.  (D) RT- qPCR showing mRNA levels in 
HEK293T cells treated with control or WIZ siRNA for 48 hours, normalized to B2M mRNA levels.  Error 
bars represent the standard deviation of three biological replicates.  P-value is indicated.  (E) Western 
blots of WCE from HEK293T cells treated with control or WIZ siRNA for 48 hours.  (F) Densitometry of 
western blot bands represented by Fig. 1E.  Error bars represent the standard deviation of three biological 
replicates. X-axis shows the G9a, WIZ, H3K9me2, and H3 signals.  Y-axis shows the fold change in 
densitometry signal of WIZ siRNA knockdown relative to control.  P-values are indicated.  (G) RT- qPCR 
showing mRNA levels in HeLa FLAG-HA-G9a cells stably transfected with control or WIZ shRNA, 
normalized to B2M mRNA levels.  Error bars represent the standard deviation of four biological replicates.  
P-values are indicated.  NS is no significant difference.  (H) Western blots of WCE and FLAG IP from 
HeLa FLAG-HA-G9a cells stably transfected with control or WIZ shRNA.  (I) Densitometry of western 
blot bands represented by Fig. 1H.  Error bars represent the standard deviation of three biological 
replicates. X-axis shows the Input and G9a-FLAG IP signals for the indicated antibody.  Y-axis shows the 
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fold change in WIZ shRNA densitometry signal relative to control input signal.  P-values are indicated.  
NS is not significant. 
 
Figure 2.  A combination of enzymatic inhibition and reduction in WIZ protein levels has an 
additive effect on G9a chromatin localization.  (A) RT-qPCR showing G9a, GLP, and WIZ mRNA 
levels in HEK293T cells treated with control or WIZ siRNA in combination with vehicle (DMSO) or 1 
µM UNC0638 for 48 hours.  Error bars represent the standard deviation of three biological replicates.  (B) 
Western blots of fractionated lysates from HEK293T cells treated with control or WIZ siRNA in 
combination with vehicle (DMSO) or 1 µM UNC0638 for 48 hours.  The fractions are total (input), 
chromatin, and soluble.   
 
Figure 3.  UNC0638 treatment increases G9a protein levels but does not affect protein stability.  (A) 
HeLa FLAG-HA-G9a cells were treated with vehicle control (DMSO), 1 µM UNC0638, or WIZ siRNA 
or control siRNA for 48 hours, or 1 µM MG132 for 12 hours, followed by 50 µg/mL CHX or vehicle 
control (ethanol) for the indicated time.  Whole cell extracts were western blotted with antibody against 
G9a or histone H3.  (B) G9a protein levels were assessed by western blot following treatment with an 
inhibitor of de novo protein synthesis, cycloheximide (CHX), in the presence of MG132 proteasome 
inhibitor, UNC0638, or WIZ siRNA knockdown.  HeLa FLAG-HA-G9a cells were treated with vehicle 
control (DMSO), 1 µM UNC0638 for 48 hours, or 1 µM MG132 for 12 hours, followed by 25 µg/mL 
CHX or vehicle control (ethanol) for the indicated time.  Whole cell extracts were western blotted with 
antibody against G9a or COXIV.   
 
Figure 4.  WIZ shRNA knockdown decreases the association of G9a with chromatin. (A) Western 
blot of nuclear soluble (Nuc) and chromatin (Chr) fractions from HeLa FLAG-HA-G9a cells treated with 
vehicle (DMSO) or 1 µM UNC0638 for 48 hours.  FLAG-HA-G9a was immunoprecipitated with FLAG 
agarose (Sigma).  (B) Densitometry of western blot bands from the chromatin fraction represented by Fig. 
4A.  Error bars represent the standard deviation of three biological replicates. X-axis shows the Input and 
G9a-FLAG IP signals.  Y-axis shows the percent densitometry signal, which was calculated by 
normalizing H3K9me2 band density to the respective UNC0638 or DMSO H3 input signal, then dividing 
UNC0638-treated by DMSO-treated band densities.  P-values are indicated.  NS is not significant.  (C) 
Western blot of nuclear soluble and chromatin fractions from HeLa FLAG-HA-G9a cells stably 
expressing control or WIZ shRNA knockdowns.  FLAG-HA-G9a was immunoprecipitated with FLAG 
agarose (Sigma).  (D) Densitometry of western blot bands from the chromatin fraction represented by Fig. 
4C.  Error bars represent the standard deviation of four biological replicates. X-axis shows the Input and 
G9a-FLAG IP signals.  Y-axis shows the percent densitometry signal, which was calculated as described 
for Fig. 4B.  P-values are indicated.  (E) Densitometry of western blot bands represented by the input 
samples in Fig. 4A.  Y-axis shows the fold change in signal from cells treated with UNC0638 compared 
to those treated with DMSO.  X-axis shows the G9a or WIZ signal from the nuclear soluble (Nuc) or 
chromatin (Chr) fractions.  Error bars represent the average of four biological replicates.  P-values are 
indicated.  (F) Densitometry of western blot bands represented by the input samples in Fig. 4C as 
described for Fig. 4E except error bars represent the standard deviation of five biological replicates.   
 
Figure 5.  Exogenously expressed WIZ restores G9a levels in the chromatin fraction of WIZ 
knockdown cells.  (A) The open reading frames for the large (WIZL) and small (WIZS) WIZ variants are 
shown with black arrows, and the 5’ and 3’ untranslated regions with a white bar.  Grey bars represent 
qPCR amplicons.  Location of WIZ siRNA and shRNA is indicated (same sequence targeted).  Scale is 
shown in kilobases (Kb).  RT-qPCR showing WIZ mRNA levels in HEK293T cells treated with control 
(white bars) or WIZ (black bars) siRNA for 48 hours, normalized to B2M mRNA levels.  Error bars 
represent the standard error of two biological replicates.  (B) Western blot of nuclear soluble and 
chromatin fractions from HeLa FLAG-HA-G9a cells stably expressing control or WIZ shRNA 
knockdowns, and transiently transfected with a construct expressing human WIZS cDNA (pWIZ).  
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FLAG-HA-G9a was immunoprecipitated with FLAG agarose (Sigma).  (C) Densitometry of western 
bands from the chromatin fraction from Fig. 4B.  Error bars represent the standard deviation of three 
biological replicates. X-axis shows the antibodies used for western blotting the chromatin fraction.  Y-
axis shows the percent densitometry signal, which was calculated by dividing WIZ shRNA or pWIZ band 
density by the band density for the Control shRNA sample.  P-values are indicated. 
 
Figure 6.  Loss of H3K9me2 signal after WIZ siRNA knockdown is due to reduction in G9a 
occupancy on chromatin.  G9a or H3K9me2 ChIP-seq was performed in HEK293T cells with antibodies 
against G9a or H3K9me2.  Experimental conditions shown are UNC0638 treatment compared to vehicle 
(DMSO) control at (A) 48 hours post treatment; and (B) 96 hours post treatment; and (C) WIZ siRNA 
compared to control knockdown at 72 hours post treatment.  Data are presented as the arithmetic 
difference between treated and untreated samples after normalization, and color is assigned on a range of 
-0.5 (red) to 0.5 (blue).  (D) Line plots representing the arithmetic difference in G9a signal between 
treated and untreated samples after normalization.  (E) Line plots representing the arithmetic difference in 
H3K9me2 signal between treated and untreated samples after normalization.  The scales of all X-axes are 
shown in kilobases (Kb). 
 
Figure 7.  UCSC Genome Browser snapshots of specific genomic regions.  (A-C) Changes in signal are 
highlighted in grey.  Occupancy for G9a and H3K9me2 in HEK293T cells is shown in WIZ siRNA 
knockdown (siWIZ), control siRNA knockdown (siNS), UNC0638-treated, or DMSO-treated cells.  A 
blue arrow represents transcribed regions, and scale is shown in kilobases (Kb) in the top right corner. 
 
Figure 8.  Genomic distribution of G9a.  (A) The percent distribution of genomic regions with G9a 
ChIP signal is plotted relative to the genomic coverage of those features.  (B) The percent distribution of 
regions where G9a signal is lost following WIZ siRNA treatment is plotted.  (C) Line plot showing the 
average ChIP signal in HEK293 cells for H3K4me3 (red line) and CTCF (black line) centered around 
regions that lose G9a signal after WIZ siRNA treatment (blue line).  Scale is shown in kilobases (Kb).  
Left X-axis represents the average ChIP-seq signal for H3K4me3 and CTCF (data from ENCODE).  
Right X-axis represents the average ChIP-seq signal for G9a (WIZ siRNA – control siRNA signal). 
 
Figure 9.  RT-qPCR data from samples used for gene expression microarray analysis.  (A) RT-
qPCR showing G9a mRNA levels in HEK293T cells treated with control siRNA (white bars) or G9a 
siRNA (black bars) for 48 hours, normalized to B2M mRNA levels.  Error bars represent the standard 
deviation of three biological replicates.  (B) RT-qPCR showing indicated transcript levels in HEK293T 
cells treated with control siRNA (white bars) or WIZ siRNA (black bars) for 48 hours, normalized to B2M 
mRNA levels.  Error bars represent the standard error of two biological replicates.  (C) RT-qPCR 
showing indicated transcript levels in HEK293T cells treated with DMSO (white bars) or UNC0638 
(black bars) for 48 hours, normalized to B2M mRNA levels.  Error bars represent the standard deviation 
of three biological replicates. 
 
Figure 10.  Microarray data indicates that enzymatic inhibition and WIZ siRNA knockdown have 
both overlapping and distinct effects on gene expression.  (A) Heatmap of genes with a similar 
expression pattern relative to control. Red indicates genes that have increased expression compared to 
control; green indicates genes that have decreased expression compared to control.  (B) Heatmap of 
differentially expressed genes between HEK293T cells with UNC0638 versus WIZ siRNA knockdown. 
Gene expression has been median centered to highlight the magnitude of differential expression.  Lane 
numbers indicate biological replicates.  (C) Comparison of gene expression and G9a occupancy.  Loss of 
G9a occupancy in WIZ siRNA knockdown HEK293T cells correlates with a reduction in gene expression 
of a subset of genes (listed as Nearest Gene).  Gene expression is represented as fold change in gene 
expression relative to control from -2.0 fold (blue) to 2.0 fold (red).  G9a occupancy is represented as fold 
change in G9a occupancy relative to control from -2.0 fold (blue) to 2.0 fold (red). 
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Figure 11.  Silver stained gels showing purified samples submitted for mass spectrometry analysis.  
Tandem affinity purification of G9a was performed with FLAG followed by HA.  HA elution samples 
were submitted for mass spectrometry analysis.  The FLAG elution (FLAG elute), and HA purification 
unbound (HA UB) samples are shown for reference.  (A) Purification from HeLa FLAG-HA-G9a cells 
treated with DMSO or 1 µM UNC0638 for 48 hours.  (B) Purification from HeLa FLAG-HA-G9a cells 
with either control shRNA or WIZ shRNA stable knockdown.   
 
Figure 12.  G9a-interacting proteins.  (A) Proteins that significantly interact with G9a.  Significantly 
interacting protein (SAINT) analysis was performed on proteomic data from FLAG-HA-G9a tandem 
affinity purifications.  Black box represents the bait protein, G9a; blue boxes are SAINT ≥ 0.9; white 
boxes are SAINT ≥ 0.8; red lines are known interactions; black lines are novel interactions. (B) Heat map 
showing changes in normalized spectral abundance factor (NSAF) data from G9a tandem affinity 
purifications in (A).  Treatment conditions are listed on top, while protein names are listed on the left side.   
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